This page shows the latest Daichii Sankyo news and features for those working in and with pharma, biotech and healthcare.
Collaboration aims to establish comprehensive database to accelerate drug development. . Japanese pharmaceutical firms Astellas, Daiichi Sankyo and Takeda have joined forces to create a comprehensive database of biomarkers from healthy adults.
AstraZeneca has announced a new co-commercialisation agreement with Daiichi Sankyo for the constipation drug Movantik (naloxegol) in the US. . ... AstraZeneca will be responsible for all manufacturing, will book all sales and will make sales-related
Daichii Sankyo is developing edoxaban tosylate, which is also an orally active direct factor Xa inhibitor.
Its clients include US and EU pharmaceutical and biotechnology corporations including Allergan, Biogen Idec, Bristol-Myers Squibb, sanofi-aventis and Daichii Sankyo.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...